Retension Pharmaceuticals IPO: $12 pricing on 2026-10-08
Retension Pharmaceuticals priced 3,750,000 shares at $12 in its dated 2026-10-08 announcement, with approximately $45.0 million base gross proceeds.
Dated offering terms — 2026-10-08
Retension Pharmaceuticals announced a price of $12 for 3,750,000 shares, representing about $45.0 million before fees. Its announcement expected Nasdaq Capital Market trading under RTSN on 9 October 2026. Closing was expected on 13 October 2026, subject to conditions.
Retension develops medicines for hypertension and cardiovascular disease. It intends to fund completion of RTN-001's Phase 2b study in uncontrolled hypertension and preparations for a planned Phase 3 trial. All base shares are company-issued.
What the financing changes
The key distinction is between completing an existing study and having enough capital to execute the next development stage. Preparation spending does not mean a pivotal trial is fully financed or will succeed. Future disclosures should connect available cash with enrollment assumptions, trial duration and milestones. That creates a more useful framework than comparing offering size alone. An eventual clinical readout may matter more to the business than short-term changes in the share price.
The trading timetable above records the issuer's expectations at pricing; it is not a live market-price quotation.
Primary sources
Retension Pharmaceuticals — pricing announcement, 2026-10-08